Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9481270 | 0.72 | — | — | |
| SCHEMBL8655905 | 0.72 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL13085699 | 0.72 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2HDAC4HDAC8 | |
| SCHEMBL3292833 | 0.68 | — | — | |
| SCHEMBL8565629 | 0.68 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL17268490 | 0.67 | GABRG2 (0.40) | ALDH1A1SMN1; SMN2HDAC4HDAC8 | |
| SCHEMBL9480201 | 0.67 | RECQL (0.36) | — | |
| SCHEMBL8563824 | 0.67 | MAPT (0.33) | SMN1; SMN2 | |
| SCHEMBL21646563 | 0.65 | SMN1; SMN2 (0.35) | ALDH1A1SMN1; SMN2HDAC4HDAC8 | |
| SCHEMBL84460 | 0.65 | LOX (0.48) | ALDH1A1SMN1; SMN2HDAC4HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | GE PING | 2008-05-08 | — | — | US | disclosed |
| US-7223778-B2 | 5-substituted-2-arylpyridines | NEUROGEN CORPORATION (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1392302-A1 | 5-SUBSTITUTED-2-ARYLPYRIDINES AS CRF1 MODULATORS | NEUROGEN CORPORATION (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030152520-A1 | 5-Substituted-2-arylpyridines | NEUROGEN CORPORATION | 2003-08-14 | — | — | US | disclosed |
| WO-2002096421-A1 | 5-SUBSTITUTED-2-ARYLPYRIDINES AS CRF1 MODULATORS | NEUROGEN CORPORATION (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030152520-A1 | 5-Substituted-2-arylpyridines | HTR5A, CRHR2, HTR2C | ALDH1A1 2270/4885SMN1; SMN2 699/4885HDAC4 1584/4885 |
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | CRHR2, CRHR1, HTR2C | ALDH1A1 2866/4885SMN1; SMN2 1354/4885HDAC4 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.